tiprankstipranks
Trending News
More News >
Privia Health Group, Inc. (PRVA)
:PRVA
US Market
Advertisement

Privia Health Group (PRVA) AI Stock Analysis

Compare
194 Followers

Top Page

PRVA

Privia Health Group

(NASDAQ:PRVA)

Rating:73Outperform
Price Target:
$24.00
▲(10.34% Upside)
Privia Health Group's strong financial performance and positive earnings call are the most significant factors driving the score. However, the high P/E ratio suggests overvaluation, and technical indicators point to potential short-term volatility.
Positive Factors
Financial Performance
Privia Health's strong second-quarter results highlight the strength of its flexible payer-, patient-, and reimbursement-agnostic operating model.
Market Strategy
The Arizona market entry is expected to be EBITDA positive faster than historical partnerships, driving further conviction into earnings growth.
Revenue Growth
The company continues to successfully expand its platform with significant growth in implemented providers and attributed lives.
Negative Factors
Guidance Communication
The lack of providing specific updated guidance ranges to some extent prevents Privia from getting the full credit of its strong 1H performance and management's confidence in business in 2H.
Industry Environment
Despite the challenging macro environment for the industry, PRVA continues to show consistent performance given the natural hedges within the business.

Privia Health Group (PRVA) vs. SPDR S&P 500 ETF (SPY)

Privia Health Group Business Overview & Revenue Model

Company DescriptionPrivia Health Group (PRVA) is a national physician organization that partners with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reduce healthcare costs. The company operates in the healthcare services sector, offering a comprehensive platform that integrates technology, team-based care, and a value-based care model to support physicians and enhance clinical outcomes. Privia Health's services include practice management, revenue cycle management, and population health management, aiming to deliver high-quality, coordinated care across various settings.
How the Company Makes MoneyPrivia Health Group primarily generates revenue through a mix of management services agreements and shared savings from value-based care arrangements. The company partners with independent physician practices, providing them with a suite of services such as practice management, billing, and technology solutions in exchange for a percentage of practice revenue. Additionally, Privia Health engages in value-based care contracts with payers, earning performance-based incentives when they achieve specific healthcare quality and cost-efficiency metrics. These value-based arrangements often involve shared savings mechanisms, where Privia Health and its partners share in the cost savings achieved through improved care coordination and patient outcomes. Key factors contributing to Privia Health's earnings include its ability to scale its platform, expand its network of affiliated physicians, and effectively manage patient populations to generate shared savings.

Privia Health Group Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
Privia Health reported strong growth in provider signings, attributed lives, and financial performance, exceeding expectations and raising guidance for 2025. The company maintains a solid cash position and financial flexibility, with positive contributions from shared savings. However, the guidance for the second half is cautious due to market uncertainties, and there are challenges in maintaining growth in existing markets.
Q2-2025 Updates
Positive Updates
Strong New Provider Signings and Growth
Implemented Provider growth of 13.8% and value-based lives attribution growth of 15.2% year-over-year helped drive total Practice Collections growth of 18.5% in the second quarter.
Financial Performance Exceeds Expectations
Adjusted EBITDA increased 31.6%, with EBITDA margin as a percentage of Care Margin expanding 310 basis points. The company raised its 2025 outlook to above the high end of initial guidance ranges for several key metrics.
Cash Position and Financial Flexibility
Ended the second quarter with more than $390 million in cash and no debt. Expecting to end the year with more than $450 million in cash, providing significant financial flexibility.
Broad-Based Market Growth
The company serves 1.38 million attributed lives across over 100 commercial and government value-based care programs, with new provider growth and entry into Arizona contributing to a 15.2% increase in total attributed lives.
Positive Shared Savings Contribution
Shared savings revenue came in better than expectations, contributing positively to care margin and EBITDA.
Negative Updates
Prudent Guidance for Second Half
Guidance reflects a prudent approach due to uncertainties in shared savings true-ups and utilization trends, leading to a conservative outlook for the second half compared to the first.
Existing Market Challenges
Facing challenges in maintaining growth momentum in existing markets, although continued expansion and late adopters provide opportunities.
Company Guidance
During the Privia Health Second Quarter 2025 Conference Call, the company provided a robust guidance update for the remainder of 2025, citing strong financial and operational performance. Key metrics included a 13.8% year-over-year growth in Implemented Providers and a 15.2% increase in value-based lives attribution, driving a total Practice Collections growth of 18.5% for the quarter. Adjusted EBITDA saw a notable 31.6% rise, with an EBITDA margin expansion of 310 basis points. Consequently, Privia Health raised its full-year 2025 outlook to exceed the high end of initial guidance for Practice Collections, GAAP revenue, platform contribution, and adjusted EBITDA. The company anticipates ending the year with over $450 million in cash, reflecting its strong balance sheet and ongoing strategic investments.

Privia Health Group Financial Statement Overview

Summary
Privia Health Group demonstrates strong financial performance with significant revenue growth, efficient cost management, and robust equity backing. However, attention is needed on fluctuations in EBIT margins and free cash flow growth.
Income Statement
85
Very Positive
Privia Health Group has shown impressive revenue growth over the years, with the latest figure reaching $1.74 billion, a significant increase from previous years. The gross profit margin is robust, indicating efficient cost management. Despite a slight decline in EBIT and EBITDA margins in the latest year, the company maintains a positive net profit margin, showcasing profitability. However, the fluctuation in EBIT margins could be a point of concern.
Balance Sheet
80
Positive
The company exhibits a strong equity base, with a healthy debt-to-equity ratio indicating low leverage, which is favorable for stability. The return on equity has improved over the years, reflecting effective utilization of shareholder funds. A high equity ratio further underscores financial robustness, though continuous monitoring of debt levels is advised.
Cash Flow
78
Positive
Privia Health Group has demonstrated consistent growth in operating cash flow, which is a positive indicator of cash-generating efficiency. The operating cash flow to net income ratio is strong, suggesting effective conversion of earnings into cash. However, the free cash flow growth rate has experienced some volatility, signaling potential fluctuations in cash availability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.90B1.74B1.66B1.36B966.22M817.08M
Gross Profit186.74M176.85M161.50M134.78M63.66M82.58M
EBITDA30.14M24.25M27.18M-14.55M-214.97M27.22M
Net Income14.84M14.38M23.08M-12.06M-190.65M31.24M
Balance Sheet
Total Assets1.27B1.14B999.90M792.81M686.37M328.97M
Cash, Cash Equivalents and Short-Term Investments390.13M491.15M389.51M347.99M320.58M84.63M
Total Debt6.64M5.59M8.29M11.50M46.50M33.66M
Total Liabilities539.00M452.34M392.51M273.76M236.19M185.32M
Stockholders Equity682.86M635.18M561.44M499.09M426.87M146.75M
Cash Flow
Free Cash Flow96.87M109.28M80.67M47.09M54.51M38.51M
Operating Cash Flow91.86M109.28M80.78M47.20M55.06M38.89M
Investing Cash Flow-96.32M-11.98M-42.97M-104.00K-32.77M-380.00K
Financing Cash Flow7.24M4.33M3.71M-19.68M213.66M-767.00K

Privia Health Group Technical Analysis

Technical Analysis Sentiment
Positive
Last Price21.75
Price Trends
50DMA
20.89
Positive
100DMA
22.14
Negative
200DMA
22.29
Negative
Market Momentum
MACD
0.29
Negative
RSI
59.68
Neutral
STOCH
68.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRVA, the sentiment is Positive. The current price of 21.75 is above the 20-day moving average (MA) of 20.64, above the 50-day MA of 20.89, and below the 200-day MA of 22.29, indicating a neutral trend. The MACD of 0.29 indicates Negative momentum. The RSI at 59.68 is Neutral, neither overbought nor oversold. The STOCH value of 68.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRVA.

Privia Health Group Risk Analysis

Privia Health Group disclosed 55 risk factors in its most recent earnings report. Privia Health Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Privia Health Group Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
$4.25B81.091.60%20.60%
73
Outperform
$2.63B182.982.32%12.05%-2.46%
71
Outperform
$1.83B-15.97%16.29%66.01%
66
Neutral
$1.50B67.361.87%6.39%
61
Neutral
$2.13B116.553.56%3.20%-24.79%-78.38%
55
Neutral
$1.09B-13.38%-6.71%-71.40%
51
Neutral
$7.83B-0.18-40.10%2.29%21.46%-2.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PRVA
Privia Health Group
21.75
1.56
7.73%
OMCL
Omnicell
33.23
-12.03
-26.58%
PINC
Premier
26.25
6.85
35.31%
EVH
Evolent Health
9.62
-22.24
-69.81%
PHR
Phreesia
31.99
6.56
25.80%
BTSG
BrightSpring Health Services, Inc.
23.93
11.17
87.54%

Privia Health Group Corporate Events

Executive/Board ChangesShareholder Meetings
Privia Health Group Approves Key Proposals at Meeting
Positive
May 22, 2025

On May 21, 2025, Privia Health Group held its 2025 Annual Meeting of Stockholders via live webcast, where all three proposals were approved. The election of three Class III directors, approval of executive compensation on a non-binding basis, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 were confirmed, indicating strong shareholder support and stability in corporate governance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025